Streetbeat News

Analyst Ratings

GMAB

Morgan Stanley analyst Vikram Purohit has maintained an Equal-Weight rating on Genmab (NASDAQ:GMAB) with a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:36 pm

WSM

Jefferies analyst Jonathan Matuszewski has upgraded Williams-Sonoma (NYSE:WSM) from Hold to Buy and increased the price target from $148 to $156.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:36 pm

SKT

Compass Point analyst Floris Van Dijkum has maintained a Buy rating on Tanger (NYSE:SKT) and raised the price target from $32 to $34.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:33 pm

ENGN

Morgan Stanley analyst Jeffrey Hung maintains an Overweight rating on enGene Holdings (NASDAQ:ENGN) with a $40 price target.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:32 pm

BIOX

Canaccord Genuity has maintained a Buy rating on Bioceres Crop Solutions but lowered the price target from $17 to $12.5.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:26 pm

ACET

Canaccord Genuity has maintained a Buy rating on Adicet Bio (NASDAQ:ACET) but has significantly lowered the price target from $19 to $8.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:25 pm

GME

Wedbush analyst Michael Pachter reiterated an Underperform rating on GameStop (NYSE:GME), lowering the price target from $11 to $10. Pachter questions GameStop's premium trading price relative to its cash reserves, citing a lack of strategic direction and potential store closures. The analyst suggests GameStop could operate as a bank to manage losses, given the challenges of digital game sales and declining hardware sales.

Portfolio Pulse from Chris Katje

September 11, 2024 | 3:14 pm

BXP

Scotiabank analyst Nicholas Yulico has maintained a Sector Outperform rating on BXP (NYSE:BXP) and increased the price target from $76 to $82.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 3:12 pm